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Dr John E. Mayer, Jr. (Boston, Mass). Congratulations on
a very interesting study and on successfully overcoming the tech-
nical challenges of both the cell seeding problem and the implant
of these tiny vascular grafts. Thank you for sending the manuscript
and figures in advance.
I have a couple of specific questions and then a more general
one. First of all, what was the thickness of the cell layers that
were wrapped around the scaffolds? Do you think that nutrient dif-
fusion limitations contributed to the apoptosis and the falling num-
bers of seeded cells in the grafts?
Dr Hibino. Thank you so much for your comment, Dr Mayer.
The thickness of the cell sheet is about 100 mm. Dr Okano’s
group, which developed this cell sheet technique, showed electri-
cal coupling of double-layered neonatal rat cardiomyocyte sheets
in vitro. They also reported 3-dimensinoal myocardial sheet tissueThe Journal of Thoracic and Caconstruction using 4-layer sheets in vivo. Based on these studies,
our iPS sheet seems to have sufficient nutrient support by simple
diffusion.
Dr Mayer. The second question is, do you know whether the
cells that you have wrapped around your scaffold actually pene-
trate into the luminal surface before implant? If not, then you
just had bare scaffold facing the bloodstream. How did you prevent
thrombosis?
DrHibino.Wedid not examine the exact luminal penetration of
the iPS cells, but the iPS cells should attach each other very
strongly because other previous studies demonstrated there is
a gap junction communication between the cells by the expression
of connexin 43 in various cell types. In addition, our previous study
using bone marrow mononuclear cell-seeded grafts demonstrated
that our SCID/beige mouse model showed almost 100% patency
even in the venous circulation because of the deficiency of the im-
mune function and platelet function.
Dr Mayer. So did you use heparin or any other anticoagulants
around the time of implant?
Dr Hibino. No, we did not use any anticoagulant.
Dr Mayer. Finally, the last questions, and the big questions re-
ally, are, first, how can we control the teratoma formation, and sec-
ond, can you speculate on the specific paracrine effects that seem
to be active here as opposed to there just being implantation cell
effects?
Dr Hibino. Regarding the prevention of teratoma formation,
enhanced purification of differentiated iPS cells would be the
most important factor. So our collaborator at the Yale stem cell
center is developing an improved method for this problem. They
insert green fluorescent protein with a specific promoter gene to in-
duce the differentiation to the vascular cell lineage and are then
able to select green fluorescent protein-positive cells later.
Regarding the possible paracrine mechanism for neovessel for-
mation, we are looking for the effect of specific cytokines such as
transforming growth factor-beta, fibroblast growth factor, or
monocyte chemotactic protein-1 using a transgenic mouse model.
Additional purification of differentiated iPS cells and an under-
standing of the combination of specific cytokines would be
a very important factor in the future.rdiovascular Surgery c Volume 143, Number 3 703
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